BioAtlantis will bring Digestica to the market in 2023 to help humans prime the body to deal with methabolic issues
Human

BioAtlantis is developing nutraceutical compositions targeting immunological, metabolic and stress-related conditions in humans. This technology is based on the use of natural compounds that modulate biological processes in humans, with efficacy proven in a diverse range of cohorts. Our flagship nutraceutical, Digestica®, is based on a unique composition that works in vivo to address immunological and metabolic abnormalities. The market launch is planned for 2023.